To confirm that the anti-tumor effect of compound BDF-1253 was mediated through the inhibition of BRD4, the mRNA expression and protein abundance of BRD4 downstream effectors associated with cancer development, including c-Myc, Bcl-2, and CDK6, were checked after the treatment of compound BDF-1253. Here, BCL2 is linked to cancer.